Aprinoia tackles tau

How Aprinoia is targeting tauopathies via imaging tracers, mAbs, small molecules

Aprinoia Therapeutics Inc. is developing a pipeline targeting tauopathies that includes diagnostic imaging tracers, mAbs specific to pathologic tau and small molecules that bind to tau rather than dissociate tau aggregates.

“We are going to develop imaging biomarkers for all the therapeutic targets first to see those targets, and then find therapies,” CEO Ming-Kuei Jang told BioCentury.

The company’s lead diagnostic, APN-1607, is a second-generation tau PET imaging compound in Phase I

Read the full 719 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE